• Trump announces agreements with nine pharmaceutical companies to reduce drug prices.
• The new deals aim to align US drug prices with those in other developed nations.
• Participating companies include Amgen, Merck, and Gilead Sciences.
• Prices for some drugs will be sold at discounts through the upcoming TrumpRx platform.
• The agreements also include commitments to invest over $150 billion in US manufacturing and R&D.

President Donald Trump has announced new agreements with nine major pharmaceutical companies aimed at significantly reducing prescription drug prices in the United States. The participating companies include Amgen, Bristol Myers Squibb, Gilead Sciences, and others, marking a concerted effort to bring US drug costs in line with those paid in other wealthy nations, which are often significantly lower. "We were subsidising the entire world. We’re not doing it anymore," Trump stated during the announcement according to aljazeera, CBS News, and India Times.

The agreements stipulate that pharmaceutical companies will offer drugs to Medicaid recipients at "most-favored-nation" pricing, matching the lowest prices offered in other developed countries. Additionally, the Trump administration's TrumpRx program will list medications available at deep discounts, allowing Americans access to more affordable drugs. "Starting next year, American drug prices will come down fast and furious and will soon be the lowest in the developed world," Trump emphasized during his press briefing CBS News and India Times.

In total, 14 out of the 17 largest pharmaceutical companies have agreed to the new pricing agreements, which include pledges to invest over $150 billion in US-based manufacturing and research and development. Some companies have also committed to donating essential pharmaceutical ingredients to a national reserve that would assure supply during emergency situations. The anticipated result of these agreements is a "massive savings" on medications for low-income Medicaid recipients according to aljazeera, CBS News, and India Times.

Despite these promising announcements, experts have raised questions about the actual impact on Medicaid patients, who may already face lower prices due to existing price protections within the program. While the initiative aims to create more equitable access to medications, the detailed execution of these pricing strategies remains to be seen, especially for injectable drugs which will not be available through the direct-to-consumer TrumpRx platform CBS News and India Times.